e-Therapeutics plc Management Update (8368J)
14 September 2016 - 9:08PM
UK Regulatory
TIDMETX
RNS Number : 8368J
e-Therapeutics plc
14 September 2016
e-Therapeutics plc
('e-Therapeutics' or 'the Company')
Management Update
Oxford, UK, 14 September 2016 - e-Therapeutics plc (AIM :ETX)
announces that following its full year results statement on 22
March 2016 which highlighted the Company's strategic refocus on its
discovery platform, Steve Self will stand down as Development
Director and leave the Company on 30 September 2016.
Iain Ross, Executive Chairmen, commented: "Steve joined
e-Therapeutics in December 2010 following a distinguished career at
The Wellcome Foundation, Boots Healthcare and as R&D Director
of Merck's Generic Global business. We thank him for his
significant contribution to our activities and wish him continuing
success in his new endeavours."
-Ends-
Contacts:
e-Therapeutics plc Tel: +44 (0) 1993 883
Iain Ross, Chairman 125
Steve Medlicott, Finance Director www.etherapeutics.co.uk
Numis Securities Limited Tel: +44 (0) 207 260
Michael Meade / Freddie Barnfield 1000
(Corporate Finance) www.numis.com
James Black (Corporate Broking)
Instinctif Partners Tel: +44 (0) 207 457
Melanie Toyne Sewell / Jayne 2020
Crook Email: e-therapeutics@instinctif.com
About e-Therapeutics plc
e-Therapeutics (AIM: ETX) is a drug discovery company with a
proprietary discovery platform based on advances in network
pharmacology and chemical biology.
The Company is applying its platform to the discovery of new
drug candidates. The therapeutic focus of the Company's activity is
in immuno-oncology, addressing drug resistance in targeted cancer
therapies and anti-infectives. The platform is highly productive,
yielding multiple potent and selective molecules at a much higher
rate and more quickly than is reported for conventional drug
discovery.
e-Therapeutics has a variety of preclinical stage assets,
including ETX1153c, a functionally resistance-less antibiotic;
ETS2300, telomerase inhibition in anti-cancer; ETS3100, small
molecule anti-TNF<ALPHA>; ETS2400, Hedgehog pathway
inhibition and ETS5200, broad spectrum antivirals. The Company has
recently completed a phase IIb clinical trial for ETS6103, a drug
to treat major depressive disorder.
The Company is fully funded to advance its drug discovery
programmes. It is based in Oxford and Newcastle, UK. For more
information, visit www.etherapeutics.co.uk.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCFZLFFQKFBBBQ
(END) Dow Jones Newswires
September 14, 2016 07:08 ET (11:08 GMT)
E-therapeutics (LSE:ETX)
Historical Stock Chart
From Apr 2024 to May 2024
E-therapeutics (LSE:ETX)
Historical Stock Chart
From May 2023 to May 2024